Mumbai, January 28, 2025 – Cipla Limited (NSE: CIPLA, BSE: 500087) has posted a 50% year-on-year (YoY) increase in net profit for Q3 FY25, reaching ₹1,571 crore, driven by strong performance in India, North America, and emerging markets. The company’s revenue from operations rose by 8% YoY to ₹7,073 crore, while EBITDA improved by 16% YoY, reflecting better operating efficiency.
Key Financial Highlights – Q3 FY25 (Consolidated)
| Metric | Q3 FY25 | Q3 FY24 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹7,073 crore | ₹6,506 crore | +8% |
| EBITDA | ₹1,989 crore | ₹1,719 crore | +16% |
| EBITDA Margin | 28.1% | 26.3% | +184 bps |
| Net Profit (PAT) | ₹1,571 crore | ₹1,056 crore | +50% |
| PAT Margin | 22.2% | 16.1% | +617 bps |
| R&D Investment | ₹360 crore | ₹300 crore | 5.1% of revenue |
Regional Performance & Business Segments
1. India Business (44% of total revenue)
- Revenue: ₹3,146 crore (+10% YoY).
- Chronic segment growth: Increased to 61.5% of the domestic portfolio.
- Branded prescription growth: Strong momentum in respiratory, urology, and cardiac therapies.
2. North America (27% of revenue)
- Revenue: $226 million (+2% YoY).
- Albuterol market share: Increased to 21%, ranked #1 in the U.S. generic market.
- FDA classification: Goa facility received Voluntary Action Indicated (VAI) status, clearing regulatory hurdles.
3. Emerging Markets & Europe (12% of revenue)
- Revenue: $98 million (+20% YoY).
- New launches and portfolio expansion in key global markets.
4. South Africa & One Africa (14% of revenue)
- Revenue: ZAR 1,196 million (+8% YoY).
- Ranked #1 in the South African prescription market.
- 13 new product launches across key therapies.
Key Product Developments & Innovations
- Afrezza (Inhaled Insulin): Exclusive marketing & distribution partnership with MannKind Corporation for India.
- Zemdri (Plazomicin): Approval for urinary tract infections (cUTI) treatment.
- Cipenmet (Cefepime-Enmetazobactam): Launched in partnership with Orchid Pharma for multi-drug resistant infections.
ESG & Sustainability Initiatives
- DJSI Recognition: Ranked 1st in India in Dow Jones Sustainability Index (DJSI) – Pharma.
- Environmental Milestones:
- Achieved Zero Waste to Landfill certification for 36 manufacturing units one year ahead of schedule.
- 13% reduction in freshwater withdrawal since FY20.
- 28% of total energy from renewable sources, up from 9% in FY20.
Management Commentary
Umang Vohra, Managing Director & Global CEO, Cipla, stated:"Our strong Q3 performance reflects consistent execution across geographies and product categories. With robust growth in India, expanding market share in the U.S., and strategic innovations in complex generics, we are positioned for sustained long-term growth."
Outlook & Strategic Priorities
- Expansion in complex generics & respiratory drugs for the U.S. and Europe.
- Increased investments in specialty therapies and biosimilars.
- Regulatory approvals & new product launches in key international markets.